|Day Low/High||7.17 / 7.39|
|52 Wk Low/High||1.92 / 8.78|
Investors considering a purchase of ChemoCentryx, Inc. shares, but cautious about paying the going market price of $9.08/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Investors considering a purchase of ChemoCentryx, Inc. stock, but cautious about paying the going market price of $6.88/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.
Company Reports at ASCO 2017 Gastrointestinal Cancers Symposium 24 Week Progression-Free Survival and 48 Week Overall Survival Data as it Continues to Follow Progress in Study Patients
Treatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation
Company expects additional data including progression-free survival by the end of 2016
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.